ETNB

89bio, Inc.

9.22 USD
-0.24 (-2.54%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

89bio, Inc. stock is up 1.43% since 30 days ago. The next earnings date is Aug 7, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 4 June’s closed higher than May. In the last 5 Unusual Options Trades, there were 3 CALLs, 2 PUTs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
24 Apr 16:39 17 Jan, 2025 10.00 CALL 137 148
24 Apr 16:40 17 Jan, 2025 10.00 CALL 200 148
14 May 15:14 16 Aug, 2024 10.00 PUT 200 26
20 May 13:34 16 Aug, 2024 10.00 PUT 200 251
28 May 19:56 17 Jan, 2025 12.50 CALL 243 489

About 89bio, Inc.

89bio, Inc. focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21.

  • HC Wainwright & Co.
    Tue Jun 11, 06:41
    buy
    confirm
  • Cantor Fitzgerald
    Fri May 17, 09:47
    buy
    confirm
  • HC Wainwright & Co.
    Fri May 17, 08:12
    buy
    confirm
  • HC Wainwright & Co.
    Thu May 16, 06:55
    buy
    confirm
  • Evercore Partners
    Wed May 15, 09:19
    buy
    confirm